• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sanofi - Articles and news items


FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes

Industry news / 29 November 2016 / Niamh Louise Marriott, Digital Editor

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program…


Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab…


Antibiotic-resistant ‘superbug’ bacteria found at NHS-funded factories

Industry news / 19 October 2016 / Niamh Louise Marriott, Digital Content Producer

Out of 34 sites tested, 16 were found to be harbouring bacteria resistant to antibiotics, according to the report. Resistance to three major antibiotics…


Success for Regeneron and Sanofi’s atopic dermatitis trial

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

Two placebo-controlled Phase 3 trials, evaluating dupixent in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD)…


Success for Sanofi and Regeneron’s LDL cholesterol trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo…

dengue vaccine injection

Sanofi sends half a million dengue vaccines to high risk Brazilians

Industry news / 15 August 2016 / Sanofi

Results of the study affirm the vaccine’s consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during the 25 month follow-up phase of the studies…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

Stem cell nano drug delivery applications to treat diabetes

Sanofi receives FDA approval of Adlyxin TM for treatment of adults with Type 2 Diabetes

Industry news / 28 July 2016 / Sanofi

U.S. Food and Drug Administration (FDA) have approved Sanofi’s Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes…

Medivation’s Board

Medivation in confidentiality agreements with Sanofi and others

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Medivation has entered into confidentiality agreements with parties that have expressed interest in exploring a potential transaction to acquire the company…

consumer healthcare business

Sanofi and Boehringer Ingelheim reach next step in business swap

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi’s Merial and Boehringer Ingelheim’s consumer healthcare business…


NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…


LixiLan-O and LixiLan-L meet primary endpoints

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +